BioXcel Therapeutics (BTAI) News Today $0.64 -0.02 (-3.02%) (As of 11/1/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period BioXcel Therapeutics to Present at ThinkEquity ConferenceOctober 29, 2024 | globenewswire.comHC Wainwright Issues Negative Outlook for BTAI EarningsOctober 25, 2024 | americanbankingnews.comBioXcel Therapeutics (NASDAQ:BTAI) Price Target Lowered to $5.00 at HC WainwrightOctober 24, 2024 | americanbankingnews.comBioXcel Therapeutics price target lowered to $5 from $7 at H.C. WainwrightOctober 22, 2024 | markets.businessinsider.comBioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress DisorderOctober 15, 2024 | globenewswire.comBioXcel Therapeutics (NASDAQ:BTAI) Stock, Short Interest ReportSeptember 28, 2024 | benzinga.comBioXcel ends commercial support for Igalmi as focus turns to neuro candidateSeptember 19, 2024 | msn.comBioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for AgitationSeptember 19, 2024 | globenewswire.comBioXcel Therapeutics executive sells shares worth $238September 18, 2024 | in.investing.comFMR LLC's Strategic Reduction in BioXcel Therapeutics Inc SharesSeptember 12, 2024 | finance.yahoo.comBioxcel Therapeutics Earns Buy Rating on Promising Clinical Trials and Market PotentialSeptember 7, 2024 | markets.businessinsider.comBioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaSeptember 5, 2024 | globenewswire.comBioXcel Therapeutics Inc (BX2.BE)August 29, 2024 | sg.finance.yahoo.comBioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth ConferenceAugust 7, 2024 | finance.yahoo.comBuy Rating Maintained for Bioxcel Therapeutics Amid Positive Performance and Growth ProspectsAugust 7, 2024 | markets.businessinsider.comBioXcel Therapeutics Reports Second Quarter 2024 Financial ResultsAugust 6, 2024 | markets.businessinsider.comBioXcel Therapeutics GAAP EPS of -$0.21 beats by $0.57, revenue of $1.1M in-lineAugust 6, 2024 | msn.comShort Interest in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Rises By 8.7%BioXcel Therapeutics, Inc. (NASDAQ:BTAI - Get Free Report) was the recipient of a significant growth in short interest in June. As of June 30th, there was short interest totalling 1,620,000 shares, a growth of 8.7% from the June 15th total of 1,490,000 shares. Based on an average trading volume of 588,800 shares, the days-to-cover ratio is presently 2.8 days.July 16, 2024 | marketbeat.comBioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual FilmJuly 16, 2024 | globenewswire.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Given Average Rating of "Hold" by BrokeragesShares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI - Get Free Report) have been given an average recommendation of "Hold" by the seven brokerages that are presently covering the stock, Marketbeat reports. Four analysts have rated the stock with a hold recommendation and three have assigned a buy reJune 8, 2024 | marketbeat.comVimal Mehta Sells 126,014 Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) StockJune 7, 2024 | insidertrades.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) CEO Vimal Mehta Sells 126,014 SharesBioXcel Therapeutics, Inc. (NASDAQ:BTAI - Get Free Report) CEO Vimal Mehta sold 126,014 shares of the stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $1.63, for a total value of $205,402.82. Following the transaction, the chief executive officer now owns 7,811,515 shares in the company, valued at $12,732,769.45. The transaction was disclosed in a filing with the SEC, which is accessible through this link.June 6, 2024 | marketbeat.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Short Interest Up 8.7% in MayBioXcel Therapeutics, Inc. (NASDAQ:BTAI - Get Free Report) was the recipient of a significant growth in short interest in May. As of May 15th, there was short interest totalling 1,630,000 shares, a growth of 8.7% from the April 30th total of 1,500,000 shares. Based on an average trading volume of 584,400 shares, the days-to-cover ratio is presently 2.8 days.June 1, 2024 | marketbeat.comBioXcel Therapeutics to Present at Jefferies Global Healthcare ConferenceMay 28, 2024 | globenewswire.comBioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual MeetingMay 21, 2024 | globenewswire.comHold Rating on Bioxcel Therapeutics Amid Growth Potential and Financial UncertaintiesMay 14, 2024 | markets.businessinsider.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Short Interest UpdateBioXcel Therapeutics, Inc. (NASDAQ:BTAI - Get Free Report) was the recipient of a significant decrease in short interest in the month of April. As of April 30th, there was short interest totalling 1,500,000 shares, a decrease of 28.2% from the April 15th total of 2,090,000 shares. Based on an average trading volume of 1,440,000 shares, the short-interest ratio is currently 1.0 days.May 13, 2024 | marketbeat.comBioXcel Therapeutics (NASDAQ:BTAI) Releases Earnings Results, Misses Expectations By $0.19 EPSBioXcel Therapeutics (NASDAQ:BTAI - Get Free Report) announced its earnings results on Thursday. The company reported ($0.87) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.19). BioXcel Therapeutics had a negative return on equity of 890.63% and a negative net margin of 12,974.86%. The company had revenue of $0.58 million during the quarter, compared to the consensus estimate of $0.42 million. During the same period in the prior year, the firm posted ($1.84) earnings per share.May 10, 2024 | marketbeat.comBullish Outlook: Bioxcel Therapeutics’ Revenue Surge and Promising Clinical Trials Fuel Buy RatingMay 10, 2024 | markets.businessinsider.comBioXcel Therapeutics First Quarter 2024 Earnings: Misses ExpectationsMay 10, 2024 | finance.yahoo.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comQ1 2024 BioXcel Therapeutics Inc Earnings CallMay 10, 2024 | finance.yahoo.comBTAI Stock Earnings: BioXcel Therapeutics Misses EPS, Beats Revenue for Q1 2024May 9, 2024 | investorplace.comBioXcel Therapeutics GAAP EPS of -$0.87 misses by $0.12, revenue of $0.58M misses by $0.05MMay 9, 2024 | msn.comBioXcel Therapeutics Reports First Quarter 2024 Financial ResultsMay 9, 2024 | globenewswire.comBioXcel Therapeutics Q1 2024 Earnings PreviewMay 8, 2024 | msn.com2 Contracts Traded for 20JUN24 BTI PHY DN Single Stock Dividend Neutral FutureMay 1, 2024 | msn.comShort Interest in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Declines By 16.1%BioXcel Therapeutics, Inc. (NASDAQ:BTAI - Get Free Report) was the recipient of a large decline in short interest during the month of April. As of April 15th, there was short interest totalling 2,090,000 shares, a decline of 16.1% from the March 31st total of 2,490,000 shares. Based on an average daily volume of 1,510,000 shares, the short-interest ratio is presently 1.4 days.April 29, 2024 | marketbeat.comHold Rating on Bioxcel Therapeutics Amid Strategic and Clinical Trial UncertaintiesApril 26, 2024 | markets.businessinsider.comBioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024April 25, 2024 | globenewswire.comBioXcel Therapeutics to launch phase 3 trial for at-home useApril 24, 2024 | uk.investing.comBioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual MeetingApril 24, 2024 | globenewswire.comBuy Rating Reaffirmed for BioXcel Therapeutics Amidst Expansion Opportunities and FDA-Approved IGALMI™April 23, 2024 | markets.businessinsider.comBioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market PotentialApril 22, 2024 | globenewswire.comQ1 2024 EPS Estimates for BioXcel Therapeutics, Inc. Lifted by HC Wainwright (NASDAQ:BTAI)BioXcel Therapeutics, Inc. (NASDAQ:BTAI - Free Report) - HC Wainwright boosted their Q1 2024 earnings per share estimates for shares of BioXcel Therapeutics in a report released on Monday, April 15th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.69) per shareApril 18, 2024 | marketbeat.comBioXcel Therapeutics stock target cut, retains buy ratingApril 17, 2024 | investing.comHC Wainwright Comments on BioXcel Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:BTAI)BioXcel Therapeutics, Inc. (NASDAQ:BTAI - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for BioXcel Therapeutics in a research report issued to clients and investors on Monday, April 15th. HC Wainwright analyst R. Selvaraju anticipates tApril 17, 2024 | marketbeat.comBioXcel Therapeutics (BTAI) Price Target Decreased by 9.82% to 10.71April 17, 2024 | msn.comBuy Rating Affirmed for Bioxcel Therapeutics Amid Strategic Clinical Trials and Regulatory PotentialApril 15, 2024 | markets.businessinsider.comShort Interest in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Drops By 20.7%BioXcel Therapeutics, Inc. (NASDAQ:BTAI - Get Free Report) was the target of a significant decrease in short interest during the month of March. As of March 31st, there was short interest totalling 2,490,000 shares, a decrease of 20.7% from the March 15th total of 3,140,000 shares. Currently, 10.5% of the shares of the company are sold short. Based on an average trading volume of 1,490,000 shares, the short-interest ratio is currently 1.7 days.April 13, 2024 | marketbeat.com Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Email Address Banking failure dead ahead (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soon Click here to watch it now. BTAI Media Mentions By Week BTAI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BTAI News Sentiment▼0.000.38▲Average Medical News Sentiment BTAI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BTAI Articles This Week▼13▲BTAI Articles Average Week Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ovid Therapeutics News Upexi News CytomX Therapeutics News X4 Pharmaceuticals News Vistagen Therapeutics News Ikena Oncology News IO Biotech News Aileron Therapeutics News InterCure News Protalix BioTherapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BTAI) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
